60 Degrees Pharmaceuticals Equity Warrants Exp 16 May 2028 Warrant(SXTPW),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SXTPW 60 Degrees Pharmaceuticals Equity Warrants Exp 16 May 2028 Warrant

Market Closed 11-22 16:00:00 EST

0.0200

+0.0000

0.00%

High0.0200	Low0.0200	Vol48.00
Open0.0200	D1 Closing0.0200	Amplitude0.00%
Mkt Cap0.00	Tradable Cap0.00	Total Shares0.00
T/O0.96	T/O Rate--	Tradable Shares0.00
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"SXTPW","market":"US","secType":"STK","nameCN":"60 Degrees Pharmaceuticals Equity Warrants Exp 16 May 2028 Warrant","latestPrice":0.02,"timestamp":1732309200000,"preClose":0.02,"halted":0,"volume":48,"delay":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":0,"latestTime":"11-22 16:00:00 EST","open":0.02,"high":0.02,"low":0.02,"amount":0.96,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1732525200000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":0.02,"volumeRatio":0.03678160750429391},"requestUrl":"/m/hq/s/SXTPW/tweets","defaultTab":"tweets","newsList":[{"id":"2485265051","title":"60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV","url":"https://stock-news.laohu8.com/highlight/detail?id=2485265051","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485265051?lang=en_us&edition=fundamental","pubTime":"2024-11-22 22:00","pubTimestamp":1732284000,"startTime":"0","endTime":"0","summary":"ORLANDO, FL / ACCESSWIRE / November 22, 2024 / RedChip Companies will air interviews with 60 Degrees Pharmaceuticals, Inc.  and Can-Fite BioPharma Ltd.  on the RedChip Small Stocks, Big Money show, a sponsored program on Bloomberg TV, this Saturday, November 23, at 7 p.m. Eastern Time . Bloomberg TV is available in an estimated 73 million homes across the U.S.In an exclusive interview, Geoffrey Dow, CEO and President of 60 Degrees Pharmaceuticals, appears on the RedChip Small Stocks Big Money show on Bloomberg TV to discuss the company's mission to develop and commercialize new therapies for infectious diseases. He highlights the FDA-approved antimalarial drug ARAKODA  and outlines plans to expand its indications to address other diseases, including babesiosis. Dow also emphasizes the company's commitment to addressing unmet medical needs and improving global health outcomes.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/_CGqlr_T72W08fVAOQ9fAw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/e0cfc5cb7f676adb9179054efe7f38b8","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/_CGqlr_T72W08fVAOQ9fAw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/e0cfc5cb7f676adb9179054efe7f38b8"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/60-degrees-pharmaceuticals-fite-biopharma-140000300.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["HCC","TM","BK4099","TV","BK4144","BK4100","BK4555","BK4006","BK4561","BK4585","SXTPW","ET","BK4588","03160","BK4187","BK4590","SXTP","BK4581","CANF","AIRI"],"gpt_icon":0},{"id":"2483358354","title":"60 Degrees Pharmaceuticals Inc. (SXTP) Reports Q3 Loss, Misses Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2483358354","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483358354?lang=en_us&edition=fundamental","pubTime":"2024-11-15 04:25","pubTimestamp":1731615903,"startTime":"0","endTime":"0","summary":"60 Degrees Pharmaceuticals Inc.  came out with a quarterly loss of $0.93 per share versus the Zacks Consensus Estimate of a loss of $0.60. This compares to loss of $3.60 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -55%. A quarter ago, it was expected that this company would post a loss of $3.96 per share when it actually produced a loss of $4.23, delivering a surprise of -6.82%.Over the last four quarters, the company has surpassed consensus EPS estimates just once.60 Degrees Pharmaceuticals Inc. , which belongs to the Zacks Medical - Drugs industry, posted revenues of $0.04 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 60%. This compares to year-ago revenues of $0.06 million. The company has not been able to beat consensus revenue estimates over the last four quarters.Investors should be mindful of the fact that the outlook for the industry can have a material ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/wbCMwMtKIoXj_iQA0ego4g--~B/aD01MDY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1154d43aaeb65735a640003549116295","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/wbCMwMtKIoXj_iQA0ego4g--~B/aD01MDY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1154d43aaeb65735a640003549116295"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/60-degrees-pharmaceuticals-inc-sxtp-202503433.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SXTPW","SXTP"],"gpt_icon":0},{"id":"2483133689","title":"BRIEF-60 Degrees Pharmaceuticals Posts Q3 Loss of 93 cents","url":"https://stock-news.laohu8.com/highlight/detail?id=2483133689","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483133689?lang=en_us&edition=fundamental","pubTime":"2024-11-15 03:35","pubTimestamp":1731612938,"startTime":"0","endTime":"0","summary":"BRIEF-60 Degrees Pharmaceuticals Posts Q3 Loss of 93 cents Nov 14  - 60 Degrees Pharmaceuticals Inc SXTP.O:60 DEGREES PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2024 RESULTS60 DEGREES PHARMACEUTICALS INC: QTRLY LOSS PER SHARE $0.93Further company coverage: SXTP.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nTUABJKYJK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SXTP","BK4007","SXTPW"],"gpt_icon":0},{"id":"2483335080","title":"60 Degrees Pharmaceuticals Announces Third Quarter 2024 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2483335080","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483335080?lang=en_us&edition=fundamental","pubTime":"2024-11-15 03:31","pubTimestamp":1731612660,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nTUABJKYJK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SXTP","BK4007","SXTPW"],"gpt_icon":0},{"id":"2465691715","title":"60 Degrees Pharmaceuticals, Inc. Announces Closing of $4 Million Private Placement Priced at-the-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2465691715","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2465691715?lang=en_us&edition=fundamental","pubTime":"2024-09-06 20:59","pubTimestamp":1725627540,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240906:nTUA4Q3BBB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SXTPW","BK4007","SXTP"],"gpt_icon":0},{"id":"2464379333","title":"60 Degrees Pharmaceuticals, Inc. Announces $4 Million Private Placement Priced at-the-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2464379333","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2464379333?lang=en_us&edition=fundamental","pubTime":"2024-09-04 20:00","pubTimestamp":1725451204,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240904:nTUA8SW8NH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SXTP","BK4007","SXTPW"],"gpt_icon":0},{"id":"2463080490","title":"60 Degrees Pharmaceuticals, Inc. Regains Compliance With Nasdaq Listing Requirements","url":"https://stock-news.laohu8.com/highlight/detail?id=2463080490","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2463080490?lang=en_us&edition=fundamental","pubTime":"2024-08-29 02:48","pubTimestamp":1724870921,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240828:nTUA4LV61P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","SXTPW","SXTP"],"gpt_icon":0},{"id":"2460807207","title":"60 Degrees Pharmaceuticals Second Quarter 2024 Earnings: Misses Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2460807207","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2460807207?lang=en_us&edition=fundamental","pubTime":"2024-08-17 21:53","pubTimestamp":1723902802,"startTime":"0","endTime":"0","summary":"NasdaqCM:SXTP Earnings and Revenue History August 17th 2024. All figures shown in the chart above are for the trailing 12 month  period. Revenue missed analyst estimates by 41%. Earnings per share  also missed analyst estimates by 152%.Looking ahead, revenue is forecast to grow 81% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in the US.The company's shares are up 39% from a week ago.It is worth noting though that we have found 6 warning signs for 60 Degrees Pharmaceuticals (5 shouldn't be ignored!) that you need to take into consideration.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/60-degrees-pharmaceuticals-second-quarter-135322846.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SXTPW","SXTP"],"gpt_icon":0},{"id":"2459485161","title":"60 Degrees Pharmaceuticals Inc. (SXTP) Reports Q2 Loss, Tops Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2459485161","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459485161?lang=en_us&edition=fundamental","pubTime":"2024-08-15 01:00","pubTimestamp":1723654802,"startTime":"0","endTime":"0","summary":"60 Degrees Pharmaceuticals Inc.  came out with a quarterly loss of $4.23 per share versus the Zacks Consensus Estimate of a loss of $3.96. This compares to loss of $16.81 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -6.82%. A quarter ago, it was expected that this company would post a loss of $1.92 per share when it actually produced earnings of $0.36, delivering a surprise of 118.75%.Over the last four quarters, the company has surpassed consensus EPS estimates just once.60 Degrees Pharmaceuticals Inc. , which belongs to the Zacks Medical - Drugs industry, posted revenues of $0.13 million for the quarter ended June 2024, surpassing the Zacks Consensus Estimate by 13.64%. This compares to year-ago revenues of $0.06 million. The company has topped consensus revenue estimates just once over the last four quarters.Investors should be mindful of the fact that the outlook for the industry can have a materia","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5w_iAw5naBqMPrzpIECi9Q--~B/aD02NzU7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/670d1917693293f70179651625deb88f","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5w_iAw5naBqMPrzpIECi9Q--~B/aD02NzU7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/670d1917693293f70179651625deb88f"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/60-degrees-pharmaceuticals-inc-sxtp-170002036.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SXTPW","SXTP"],"gpt_icon":0},{"id":"2459105938","title":"60 Degrees Pharmaceuticals Announces Second Quarter 2024 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2459105938","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459105938?lang=en_us&edition=fundamental","pubTime":"2024-08-14 23:01","pubTimestamp":1723647660,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240814:nTUA6PR0DW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","SXTP","SXTPW"],"gpt_icon":0},{"id":"2459575839","title":"Should You Add 60 Degrees Pharmaceuticals, Inc. (SXTP) to Your Stock Portfolio Right Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2459575839","media":"Insider Monkey","labels":["Business Data"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459575839?lang=en_us&edition=fundamental","pubTime":"2024-08-13 05:01","pubTimestamp":1723496512,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 10 Best New Penny Stocks To Buy Now.In this article, we are going to take a look at where 60 Degrees Pharmaceuticals, Inc.  stands against the other new penny stocks.Fears of a US recession are growing, sending stock markets down, and investors around the world are on edge. The US Bureau of Labor Statistics  released July job figures that were worse than anticipated, revealing only 114,000 new jobs generated in July compared to the predicted 175,000. These data alarmed investors, as did the disappointing latest earnings from tech giants. As a result, the manufacturing industry in the US had an eight-month low in activity and the unemployment rate reached a three-year high of 4.3% due to a decline in new contracts.“As 2024 unfolds, participants in the IPO market are entering uncharted territory. IPO candidates are influenced by the recent pivot in investors' preference toward proven profitability in an altered interest rate landscape, and are doing thi","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Q9BMZVcAQCvnsJrWWSDDMA--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/9e55142f7b4ac714c97f59842ab0f46d","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Q9BMZVcAQCvnsJrWWSDDMA--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/9e55142f7b4ac714c97f59842ab0f46d"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/add-60-degrees-pharmaceuticals-inc-210152918.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Business Data","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TQQQ","NQmain","SXTP","PSQ","QLD","MNQmain","SQQQ","QID","SXTPW",".IXIC","BK4007"],"gpt_icon":1},{"id":"2457295040","title":"60 Degrees Pharmaceuticals, Inc. Announces 1:12 Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2457295040","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2457295040?lang=en_us&edition=fundamental","pubTime":"2024-08-06 21:26","pubTimestamp":1722950760,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240806:nTUA9KN3TB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SXTPW","BK4007","SXTP"],"gpt_icon":0},{"id":"2452204694","title":"60 DEGREES PHARMACEUTICALS SIGNS CLINICAL TRIAL AGREEMENTS WITH ALL PLANNED TRIAL SITES FOR TAFENOQUINE BABESIOSIS STUDY","url":"https://stock-news.laohu8.com/highlight/detail?id=2452204694","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2452204694?lang=en_us&edition=fundamental","pubTime":"2024-07-19 20:29","pubTimestamp":1721392140,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240719:nTUAN7KWS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","LU0985320562.USD","SXTP","BK4007","ALL","BK4588","FOR","BK4107","SXTPW","LU2355687059.USD","BK4533","BK4024"],"gpt_icon":0},{"id":"2450012556","title":"60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia microti Despite Prior Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2450012556","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2450012556?lang=en_us&edition=fundamental","pubTime":"2024-07-09 18:31","pubTimestamp":1720521060,"startTime":"0","endTime":"0","summary":"The goal of the study is to confirm the findings of an 80 percent babesiosis cure rate in humans observed in a similar population in an earlier case series of tafenoquine completed by Yale School of Public Health  in April 2024 and published in the journal, Clinical Infectious Diseases. The YSPH case series showed a cure rate  of 80 percent  in a series of five immunosuppressed patients who were administered weekly tafenoquine following a loading dose in combination with standard of care medications.Tafenoquineis approved for malaria prophylaxis inthe United Statesunder the product name ARAKODA. Tafenoquinehas not been proven to be effective for treatment or prevention of babesiosis and is not approved by theU.S. Food and Drug Administration for such an indication.About the 60 Degrees Pharmaceuticals Program for Tafenoquine in Babesiosis60 Degrees Pharmaceuticals is engaged in advancing multiple clinical trials to establish the safety and efficacy of tafen","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/bxqkYhe7JzGcYN3ffH19jQ--~B/aD05NTg7dz0xODMwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/f409c5c178ca0321d32bbd132d834ddd","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/bxqkYhe7JzGcYN3ffH19jQ--~B/aD05NTg7dz0xODMwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/f409c5c178ca0321d32bbd132d834ddd"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/60-degrees-pharma-announces-irb-103100282.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SXTPW","SXTP","BK4007"],"gpt_icon":0},{"id":"2446553613","title":"First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its Kind","url":"https://stock-news.laohu8.com/highlight/detail?id=2446553613","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2446553613?lang=en_us&edition=fundamental","pubTime":"2024-06-27 19:59","pubTimestamp":1719489540,"startTime":"0","endTime":"0","summary":"First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its Kind","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240627:nTUACJKBN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","SXTPW","SXTP"],"gpt_icon":0},{"id":"2446536008","title":"First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its Kind","url":"https://stock-news.laohu8.com/highlight/detail?id=2446536008","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2446536008?lang=en_us&edition=fundamental","pubTime":"2024-06-27 19:59","pubTimestamp":1719489540,"startTime":"0","endTime":"0","summary":"The efficacy and safety of tafenoquine in treating human babesiosis will be evaluated in a randomized, double-blind, placebo-controlled trial conducted at Tufts Medical Center in Boston.Endpoints are time to sustained clinical resolution of symptoms of babesiosis, and molecular cure as determined by an FDA-approved nucleic acid test .WASHINGTON, June 27, 2024  -- 60 Degrees Pharmaceuticals, Inc.  , a pharmaceutical company focused on developing new medicines for infectious diseases, announced that the first patient has been enrolled in a randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of tafenoquine in treating babesiosis in humans. The patient was enrolled at Tufts Medical Center in Boston.The Company is in discussions with other prominent university hospitals to participate in the tafenoquine for babesiosis study.About the Tafenoquine in Babesiosis StudyThe study is a randomized, double-blind, placebo-controlled trial enrol","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/bxqkYhe7JzGcYN3ffH19jQ--~B/aD05NTg7dz0xODMwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/f409c5c178ca0321d32bbd132d834ddd","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/bxqkYhe7JzGcYN3ffH19jQ--~B/aD05NTg7dz0xODMwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/f409c5c178ca0321d32bbd132d834ddd"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/first-patient-enrolled-60-degrees-115900072.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SXTP","SXTPW","BK4007","BK4144","NAT"],"gpt_icon":0},{"id":"2442736706","title":"60 Degrees Pharmaceuticals Receives FDA Orphan Drug Designation for Tafenoquine for Treatment of Patients With Acute Babesiosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2442736706","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2442736706?lang=en_us&edition=fundamental","pubTime":"2024-06-11 19:59","pubTimestamp":1718107140,"startTime":"0","endTime":"0","summary":"60 Degrees Pharmaceuticals Receives FDA Orphan Drug Designation for Tafenoquine for Treatment of Patients With Acute Babesiosis","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240611:nTUA6WVQPP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","SXTPW","SXTP"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.4594},{"period":"1month","weight":-0.4898},{"period":"3month","weight":-0.5},{"period":"6month","weight":-0.7337},{"period":"1year","weight":-0.6928},{"period":"ytd","weight":-0.6}],"compareEarnings":[{"period":"1week","weight":0.0167},{"period":"1month","weight":0.0303},{"period":"3month","weight":0.0594},{"period":"6month","weight":0.1248},{"period":"1year","weight":0.3088},{"period":"ytd","weight":0.2529}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"exchange":"NASDAQ","name":"60 Degrees Pharmaceuticals Equity Warrants Exp 16 May 2028 Warrant","nameEN":"60 Degrees Pharmaceuticals Equity Warrants Exp 16 May 2028 Warrant"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"60 Degrees Pharmaceuticals Equity Warrants Exp 16 May 2028 Warrant(SXTPW),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest 60 Degrees Pharmaceuticals Equity Warrants Exp 16 May 2028 Warrant(SXTPW) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"60 Degrees Pharmaceuticals Equity Warrants Exp 16 May 2028 Warrant,SXTPW,60 Degrees Pharmaceuticals Equity Warrants Exp 16 May 2028 Warrant股票,60 Degrees Pharmaceuticals Equity Warrants Exp 16 May 2028 Warrant股票老虎,60 Degrees Pharmaceuticals Equity Warrants Exp 16 May 2028 Warrant股票老虎国际,60 Degrees Pharmaceuticals Equity Warrants Exp 16 May 2028 Warrant行情,60 Degrees Pharmaceuticals Equity Warrants Exp 16 May 2028 Warrant股票行情,60 Degrees Pharmaceuticals Equity Warrants Exp 16 May 2028 Warrant股价,60 Degrees Pharmaceuticals Equity Warrants Exp 16 May 2028 Warrant股市,60 Degrees Pharmaceuticals Equity Warrants Exp 16 May 2028 Warrant股票价格,60 Degrees Pharmaceuticals Equity Warrants Exp 16 May 2028 Warrant股票交易,60 Degrees Pharmaceuticals Equity Warrants Exp 16 May 2028 Warrant股票购买,60 Degrees Pharmaceuticals Equity Warrants Exp 16 May 2028 Warrant股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"60 Degrees Pharmaceuticals Equity Warrants Exp 16 May 2028 Warrant(SXTPW),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest 60 Degrees Pharmaceuticals Equity Warrants Exp 16 May 2028 Warrant(SXTPW) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction